Michael J. Thirman
迈克尔·瑟曼
MD
Professor of Medicine, Section of Hematology/Oncology医学教授，血液/肿瘤学科
👥Biography 个人简介
Dr. Michael Thirman is a leading CLL specialist and translational researcher who contributed to early clinical development of venetoclax (BCL-2 inhibitor) and novel combination regimens for CLL. His work spans clinical trials and molecular oncology research, with expertise in managing high-risk and relapsed CLL.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BCL-2 Inhibition in CLL
Participated in pioneering early clinical trials of venetoclax in relapsed/refractory CLL, helping establish time-limited therapy as a paradigm shift away from continuous treatment for CLL patients.
Leukemia Molecular Biology
Conducted foundational research on transcription factor fusions and chromosomal translocations in leukemia, providing mechanistic insights relevant to targeted therapy development.
Representative Works 代表性著作
Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine (2016)
Landmark trial demonstrating high response rates with venetoclax in high-risk relapsed/refractory CLL including 17p-deleted cases.
Cloning of ENL, the Gene Fused with HRX in t(11;19)(q23;p13.3) Acute Leukemia
Molecular and Cellular Biology (1995)
Seminal molecular cloning work characterizing ENL-MLL fusion oncogene in acute leukemia, foundational for understanding 11q23 rearrangements.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 迈克尔·瑟曼 的研究动态
Follow Michael J. Thirman's research updates
留下邮箱，当我们发布与 Michael J. Thirman（University of Chicago Medicine, Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment